News
4h
Stockhead on MSNHealth Check: Neuren says more patients are staying the course as US Daybue sales liftThe heavily pre-treated patients showed median progression-free survival of 29 months, which meant their tumours didn’t get bigger. Overall survival was 32 months, with a “manageable” safety profile.
Have you ever dreamed of writing a heartfelt letter, sealing it in a bottle, and letting the ocean carry it to someone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results